title: Non-ischemic cardiomyopathy patients derive superior mortality benefit from cardiac resynchronization therapy.
abstract: BACKGROUND
  Cardiac Resynchronization Therapy (CRT) is indicated for the treatment of advanced heart failure with severe systolic dysfunction and intraventricular conduction delay. Patient selection for this technology is vital, though it remains unclear which patients benefit most from CRT. We tested the hypothesis that patients with non-ischemic cardiomyopathy have a superior mortality benefit from CRT than ischemic cardiomyopathy patients.
  
  
  METHODS
  We evaluated 95 CRT patients to determine which factors predict mortality.
  
  
  RESULTS
  Patients with non-ischemic cardiomyopathy had a significantly better prognosis than patients with ischemic cardiomyopathy.
  
  
  CONCLUSIONS
  Larger prospective studies can substantiate this finding and better delineate which patients benefit most from CRT.
authors.affiliation: Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine New York, New York, USA. jrosman@chpnet.org
authors.forename: Jonathan
authors.initials: J
authors.lastname: Rosman
authors.forename: Sandeep
authors.initials: S
authors.lastname: Dhillon
authors.forename: Alexander
authors.initials: A
authors.lastname: Mayer
authors.forename: Sam
authors.initials: S
authors.lastname: Hanon
authors.forename: Schweitzer
authors.initials: S
authors.lastname: Paul